ABVC BIOPHARMA, INC. (ABVC)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue TTM

0 400K 800K 1.2M Q1 '23: 1.1M Q2 '23: 765.6K Q3 '23: 739.3K Q4 '23: 152.4K Q1 '24: 25.4K Q2 '24: 136.4K Q3 '24: 509.8K Q4 '24: 509.6K Q1 '23 Q2 '23 Q3 '23 Q4 '23 Q1 '24 Q2 '24 Q3 '24 Q4 '24

Gross Profit TTM

-250K 0 250K 500K 750K Q1 '23: 727.6K Q2 '23: 356.3K Q3 '23: 311K Q4 '23: -149.6K Q1 '24: -216.7K Q2 '24: -32.9K Q3 '24: 369.8K Q4 '24: 508.8K Q1 '23 Q2 '23 Q3 '23 Q4 '23 Q1 '24 Q2 '24 Q3 '24 Q4 '24

Operating Income TTM

-9M -6M -3M 0 3M 6M 9M Q3 '24: -4.5M Q4 '24: -4.7M Q1 '25: -2.6M Q2 '25: -4M Q3 '25: -5.7M Q4 '25: -7.2M Q1 '26: -8M Q2 '26: -6.5M Q3 '24 Q4 '24 Q1 '25 Q2 '25 Q3 '25 Q4 '25 Q1 '26 Q2 '26

Net Income TTM

-9M -6M -3M 0 3M 6M 9M Q3 '24: -4.6M Q4 '24: -4.9M Q1 '25: -2.9M Q2 '25: -4.2M Q3 '25: -5.9M Q4 '25: -7.9M Q1 '26: -8.6M Q2 '26: -7.1M Q3 '24 Q4 '24 Q1 '25 Q2 '25 Q3 '25 Q4 '25 Q1 '26 Q2 '26

Cost of Revenue TTM

0 150K 300K 450K Q1 '23: 344.8K Q2 '23: 409.4K Q3 '23: 428.2K Q4 '23: 302K Q1 '24: 242.1K Q2 '24: 169.3K Q3 '24: 140K Q4 '24: 763 Q1 '23 Q2 '23 Q3 '23 Q4 '23 Q1 '24 Q2 '24 Q3 '24 Q4 '24

Operating Cash Flow TTM

-4.5M -3M -1.5M 0 1.5M 3M 4.5M Q3 '24: -1.5M Q4 '24: -1.8M Q1 '25: -1.4M Q2 '25: -2.1M Q3 '25: -3.1M Q4 '25: -3M Q1 '26: -3.3M Q2 '26: -2.7M Q3 '24 Q4 '24 Q1 '25 Q2 '25 Q3 '25 Q4 '25 Q1 '26 Q2 '26

Free Cash Flow TTM

-10.5M -7M -3.5M 0 3.5M 7M 10.5M Q3 '12: -915.5K Q4 '12: -584.8K Q1 '13: -370.4K Q2 '13: -131.9K Q3 '13: -37.8K Q3 '22: -9.6M Q4 '22: -7.5M Q3 '12 Q4 '12 Q1 '13 Q2 '13 Q3 '13 Q3 '22 Q4 '22

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 9M 18M 27M Q1 '24: 9.7M Q2 '24: 11.3M Q3 '24: 12.4M Q1 '25: 15M Q2 '25: 17.4M Q3 '25: 23.3M Q1 '26: 25.4M Q2 '26: 26.1M Q1 '24 Q2 '24 Q3 '24 Q1 '25 Q2 '25 Q3 '25 Q1 '26 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-0.60 -0.40 -0.20 0.00 0.20 0.40 0.60 Q3 '24: -0.15 Q4 '24: -0.45 Q1 '25: -0.22 Q2 '25: -0.27 Q3 '25: -0.33 Q4 '25: -0.39 Q1 '26: -0.39 Q2 '26: -0.29 Q3 '24 Q4 '24 Q1 '25 Q2 '25 Q3 '25 Q4 '25 Q1 '26 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.